How to Lower Hematocrit on TRT Without Blood Donation

Your haematocrit came back at 0.53 and your doctor wants you to donate blood. You have been down that road before: the fatigue after donation, the iron depletion, the rebound where your levels come back even higher six weeks later. There has to be a better way.

There is. Not one strategy, but a tiered protocol based on how high your haematocrit actually is. The approach at 0.51 is completely different from the approach at 0.55, and most content online treats them as the same problem. They are not.

This article gives you the complete non-phlebotomy playbook: what to do at each threshold, which interventions have evidence behind them, which ones are gym folklore, and when you genuinely need to stop TRT and see a haematologist.

Why your haematocrit rises on TRT

Testosterone stimulates erythropoiesis directly. It suppresses hepcidin (the iron gatekeeper hormone) within 7 days of starting therapy, dropping levels by 50-60% and flooding the bone marrow with available iron for red cell production (Bachman et al., 2010). It also stimulates erythropoietin (EPO) production in the kidneys and directly activates erythroid progenitor cells in the bone marrow.

The result: more red blood cells, higher haemoglobin, higher haematocrit. This is dose-dependent. Replacement doses (100-150 mg/week of testosterone enanthate) raise haematocrit modestly. Supraphysiological doses push it higher. And certain compounds are disproportionately erythropoietic: boldenone (EQ) is notorious for this, while nandrolone potentiates EPO and oxymetholone (Anadrol) was literally FDA-approved for treating anaemia.

The threshold that matters: haematocrit above 0.52 (52%) increases blood viscosity and cardiovascular risk. Above 0.54, the risk becomes significant enough that most guidelines recommend intervention (Ohlander et al., 2018).

For the full mechanism and dose-response data, see TRT, Haemoglobin & Haematocrit.

Before you change anything: rule out confounders

A high haematocrit reading is not always a high haematocrit. Before you adjust your protocol, rule out the things that inflate the number artificially or drive it up independently of testosterone.

Dehydration at blood draw

This is the most common false alarm. Dehydration concentrates your blood, pushing haematocrit up by 2-5% on the reading. If you fasted overnight, trained that morning, had coffee but no water, and sat in a waiting room for 30 minutes, your haematocrit will read higher than your actual steady-state level.

The fix: drink 500-750 mL of water in the 2 hours before your blood draw. Do not overhydrate (that dilutes the sample in the other direction). Just normal hydration. If your haematocrit was 0.52 on a dehydrated draw, it might be 0.49 when properly hydrated. Retest before changing your protocol.

Sleep apnoea

Obstructive sleep apnoea (OSA) causes intermittent hypoxia during sleep, which triggers EPO production independently of testosterone. If you have undiagnosed OSA and you are on TRT, your haematocrit will stay elevated no matter how much you adjust your dose. A meta-analysis found that OSA is significantly associated with secondary polycythaemia, with the hypoxia-EPO pathway being the primary driver (Solmaz et al., 2015).

Risk factors in the TRT population: higher body weight (especially neck circumference above 43 cm), snoring, daytime fatigue despite "adequate" sleep, waking with headaches. If any of these apply, get a sleep study before adjusting your TRT protocol.

Smoking

Smoking raises haematocrit through chronic carbon monoxide exposure, which reduces oxygen-carrying capacity and triggers compensatory erythropoiesis. If you smoke and your haematocrit is elevated, that is a separate problem from TRT-induced erythrocytosis.

Tier 1: haematocrit 0.50-0.52 (lifestyle interventions)

At this level, your haematocrit is above the standard reference range but below the clinical concern threshold. The goal is to prevent it from climbing further without changing your TRT dose.

Hydration protocol

Chronic mild dehydration is endemic in the gym population. Most men on TRT drink enough water during training but underhydrate the rest of the day. Target 3-4 litres per day of total fluid intake, spread across the day. This is not about diluting your blood; it is about maintaining plasma volume so your haematocrit reflects actual red cell mass rather than haemoconcentration.

The timing matters for blood draws specifically: 500-750 mL in the 2 hours before the test, as noted above.

Injection frequency

This is the single most effective lifestyle intervention. Large, infrequent injections (e.g., 200 mg every two weeks) create sharp testosterone peaks that drive disproportionate EPO surges. Splitting the same weekly dose into smaller, more frequent injections blunts these peaks.

A study comparing weekly versus biweekly testosterone cypionate injections found that more frequent dosing produced more stable haematocrit levels with fewer excursions above the reference range (Coviello et al., 2008).

Practical options:

• Every-other-day (EOD) SubQ: the flattest testosterone curve, lowest erythropoietic stimulus
• Twice weekly IM/SubQ: good compromise between convenience and stability
• Daily SubQ microdosing: maximum stability, some men report this keeps haematocrit 2-3% lower than weekly injections at the same total dose

If you are currently injecting weekly or biweekly, switching to EOD or daily is the first thing to try.

Reduce dietary iron loading

Your bone marrow needs iron to make red blood cells. Testosterone has already opened the iron floodgates by suppressing hepcidin. You do not need to help it along.

If your ferritin is above 150 ug/L and your haematocrit is creeping up:

• Stop any iron supplements
• Reduce red meat intake to 2-3 servings per week (from the typical bodybuilder's daily steak habit)
• Avoid vitamin C with iron-rich meals (vitamin C increases iron absorption)
• Drink tea or coffee with meals (tannins inhibit iron absorption)

This is not about becoming iron deficient. It is about not feeding excess iron to a bone marrow that is already overproducing red cells.

Tier 2: haematocrit 0.52-0.54 (active intervention)

At this level, you are above the clinical threshold. The interventions from Tier 1 still apply, but you need to add pharmacological and protocol-level changes.

Naringin: the evidence

Naringin is a flavonoid found in grapefruit that has become the community's go-to supplement for haematocrit management. The evidence is limited but real.

A 42-day trial of grapefruit consumption showed statistically significant normalisation of erythrocyte parameters in healthy adults (Robbins et al., 1988). The proposed mechanism is twofold: naringin modulates EPO receptor sensitivity on erythroid progenitor cells (reducing the bone marrow's response to EPO), and it chelates iron in the gut, reducing absorption and limiting the substrate for new red cell production.

A separate study confirmed the safety of 400 mg/day naringin supplementation over 8 weeks, with the bonus of reducing LDL cholesterol by 17% and total cholesterol by 14% (Jung et al., 2003).

Dosing protocol (community-reported, not from clinical trials):

• 500-1000 mg/day naringin extract
• Alternative: 2-3 glasses of grapefruit juice per day (but high sugar content makes this impractical for most athletes)
• Take with meals for better absorption
• Allow 4-6 weeks to see haematocrit changes on bloodwork

CYP3A4 warning: Naringin and grapefruit inhibit the CYP3A4 enzyme. This affects the metabolism of anastrozole, statins, calcium channel blockers, and some other medications. If you take an aromatase inhibitor, check the interaction before adding naringin. The practical impact: your AI may become more potent at the same dose if you add grapefruit.

Dose reduction: 10-20%

If your haematocrit is above 0.52 and you are running testosterone at the higher end of TRT (150-200 mg/week), a 10-20% dose reduction is the most direct intervention. The relationship between testosterone dose and erythropoiesis is linear in the replacement range.

Dropping from 150 mg/week to 120 mg/week often brings haematocrit down by 1-3% over 6-8 weeks. Retest at 6 weeks after a dose change, not earlier. Haematocrit responds slowly because red blood cells live for approximately 120 days.

Switch to subcutaneous injection

Subcutaneous injection produces lower peak testosterone levels than intramuscular injection at the same dose. Lower peaks mean less EPO stimulation. A study comparing SubQ versus IM testosterone cypionate found comparable trough levels with lower peak-to-trough ratios for SubQ (Al-Futaisi et al., 2006).

If you are still injecting IM, switching to SubQ (abdomen or lateral thigh, 27-30g insulin syringe) in combination with increased frequency gives you two compounding benefits: flatter curve from SubQ plus flatter curve from more frequent dosing.

What about fish oil?

Fish oil is widely recommended in the TRT community for haematocrit management. This needs clarification: fish oil does not lower haematocrit. Omega-3 fatty acids reduce blood viscosity and platelet aggregation, which addresses the cardiovascular risk from thick blood. But your haematocrit reading on the next blood test will not change from fish oil alone.

This distinction matters because some men take fish oil, see no change in haematocrit on their labs, and conclude it is not working. It is working on viscosity and clotting risk; it is just not reducing the red cell count itself. Think of it as a safety net rather than a treatment.

EPA/DHA at 2-4 g/day is a reasonable addition to your protocol for viscosity management, but do not rely on it as your primary haematocrit intervention.

Tier 3: haematocrit above 0.54 (escalation required)

This is no longer optional optimisation. Haematocrit above 0.54 carries meaningful stroke and cardiovascular risk. You need to act, and the interventions are more aggressive.

Reduce or stop testosterone

If your haematocrit is persistently above 0.54 despite the interventions in Tiers 1 and 2, the dose is too high for your physiology, or there is a compounding factor that has not been addressed. Reduce testosterone by 25-50% and retest in 6 weeks. If it remains above 0.54, consider suspending TRT entirely until haematocrit normalises.

If you are running compounds beyond TRT (blast doses, boldenone, trenbolone), drop to TRT-only immediately. The erythropoietic load from multiple androgens is additive.

Sleep apnoea screening (mandatory at this level)

If you have not already been screened for OSA, do it now. At haematocrit above 0.54, the probability that OSA is contributing is high enough that dose adjustment alone may not solve the problem. A home sleep test (level 3 study) is the minimum; a full polysomnography (level 1) is better.

Treatment with CPAP in men with OSA has been shown to reduce haematocrit independently of any changes to testosterone dose (Krieger et al., 1990).

Rule out polycythaemia vera

Polycythaemia vera (PV) is a myeloproliferative disorder where the bone marrow overproduces red cells independently of EPO. It is rare, but haematocrit persistently above 0.54 despite dose reduction is one of its presentations. A JAK2 V617F mutation test and serum EPO level can differentiate PV from testosterone-induced erythrocytosis:

• Testosterone-induced: EPO is normal or mildly elevated, JAK2 negative
• Polycythaemia vera: EPO is suppressed (low), JAK2 positive in >95% of cases

If your haematocrit stays above 0.54 after stopping testosterone for 3 months, get these tests. This is not common, but missing it is dangerous.

When phlebotomy is actually appropriate

If haematocrit is above 0.56 or you have symptoms (headaches, visual disturbances, dizziness, flushing, tingling in extremities), therapeutic phlebotomy is the correct acute intervention. The goal is to get haematocrit below 0.52 quickly while you address the underlying cause.

The problem with routine phlebotomy as a maintenance strategy is well documented: it depletes iron stores, which paradoxically activates HIF (hypoxia-inducible factor) pathways that can increase thrombotic risk even as haematocrit drops. For the full evidence against chronic phlebotomy, see The Iron Paradox on TRT.

Monitoring protocol: what to test and when

Managing haematocrit without phlebotomy requires more frequent monitoring than standard TRT bloodwork. Here is the schedule:

Baseline (before any intervention)

• Haematocrit and haemoglobin
• RBC count
• Full iron panel: ferritin, serum iron, transferrin saturation, TIBC
• Reticulocyte count (tells you what the bone marrow is doing right now, not what it did 3 months ago)
• RDW (rising RDW with stable ferritin is the earliest warning of iron stress)

6 weeks after any protocol change

Retest haematocrit, haemoglobin, and RBC. Reticulocyte count is especially useful here: if reticulocytes are dropping, haematocrit will follow 2-4 weeks later. This gives you an early signal that your intervention is working before the haematocrit number itself changes.

Ongoing (every 3 months while haematocrit is above 0.50)

Full panel including iron studies. Once haematocrit is stable below 0.50 for two consecutive tests, you can move to 6-monthly monitoring.

For a deeper dive on interpreting the full red cell panel, see The Complete Haematology Panel for Enhanced Athletes.

Key takeaways

• Haematocrit management on TRT should be tiered by severity: 0.50-0.52 (lifestyle), 0.52-0.54 (active intervention), 0.54+ (escalation and medical workup).
• Before changing anything, rule out dehydration at blood draw, undiagnosed sleep apnoea, and smoking. A single elevated reading after a dehydrated morning draw does not warrant protocol changes.
• Injection frequency is the most effective lifestyle intervention. Switching from weekly to EOD or daily microdosing blunts the testosterone peaks that drive EPO surges.
• Naringin (500-1000 mg/day) has limited but real evidence for normalising erythrocyte parameters. Allow 4-6 weeks for effect. Watch for CYP3A4 interactions with aromatase inhibitors.
• Fish oil does not lower haematocrit. It reduces blood viscosity and clotting risk, which addresses the danger of thick blood without changing the number on your lab report.
• Dose reduction of 10-20% is the most direct pharmacological intervention at the 0.52-0.54 level. Retest at 6 weeks minimum due to the 120-day red cell lifespan.
• Above 0.54, screen for sleep apnoea and polycythaemia vera (JAK2 mutation + EPO level). Do not assume it is just the testosterone.
• Chronic phlebotomy depletes iron and can paradoxically increase thrombotic risk through HIF pathway activation. Use it for acute management above 0.56, not as routine maintenance.
• Monitor reticulocyte count for early signal of whether your intervention is working: reticulocytes drop 2-4 weeks before haematocrit follows.

---

References

1. Bachman, E., Feng, R., Travison, T., Li, M., Olbina, G., Ostland, V., Ulloor, J., Zhang, A., Basaria, S., Ganz, T., Westerman, M., & Bhasin, S. (2010). Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. Journal of Clinical Endocrinology & Metabolism, 95(10), 4743-4747. PubMed

2. Ohlander, S. J., Varghese, B., & Gendelman, K. (2018). Erythrocytosis following testosterone therapy. Sexual Medicine Reviews, 6(1), 77-85. PubMed

3. Solmaz, S., Derin, S., Ozturan, O., Oztürk, O., & Yenigun, A. (2015). Obstructive sleep apnoea and polycythaemia. European Archives of Oto-Rhino-Laryngology, 272(12), 3877-3882. PubMed

4. Robbins, R. C., Martin, F. G., & Roe, J. M. (1988). Ingestion of grapefruit lowers elevated hematocrits in human subjects. International Journal for Vitamin and Nutrition Research, 58(4), 414-417. PubMed

5. Jung, U. J., Kim, H. J., Lee, J. S., Lee, M. K., Kim, H. O., Park, E. J., Kim, H. K., Jeong, T. S., & Choi, M. S. (2003). Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clinical Nutrition, 22(6), 561-568. PubMed

6. Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology & Metabolism, 93(3), 914-919. PubMed

7. Al-Futaisi, A. M., Tamimi, Y. A., Al-Kindi, M. K., Al-Wahaibi, K. N., & Al-Busaidi, N. B. (2006). Subcutaneous administration of testosterone: a pilot study report. Sultan Qaboos University Medical Journal, 6(1), 69-72. PubMed

8. Krieger, J., Sforza, E., Delanoe, C., & Petiau, C. (1990). Decrease in haematocrit with continuous positive airway pressure treatment in obstructive sleep apnoea patients. European Respiratory Journal, 3(3), 311-314. PubMed